速递｜口服司美格鲁肽开局爆发！诺和诺德股价大涨9%

Core Viewpoint - Novo Nordisk has experienced a significant market rebound following the successful launch of its oral version of Wegovy in the U.S., which exceeded initial prescription expectations, leading to a notable increase in its stock price [4][6]. Group 1: Product Performance - The oral Wegovy achieved approximately 3,100 prescriptions in its first week post-launch, with some estimates suggesting up to 4,290 prescriptions, significantly outperforming Eli Lilly's Zepbound, which had 1,300 to 1,900 prescriptions in its first week [4]. - Clinical data from the Phase 3 OASIS 4 trial indicated that patients on a daily 25 mg oral dose of Wegovy lost an average of 13.6% of their body weight over 64 weeks, with adherence leading to a weight loss of up to 16.6%, comparable to the injectable version [6]. Group 2: Market Strategy - Novo Nordisk adopted an aggressive pricing strategy for oral Wegovy, with a starting monthly price of $149, significantly lower than the injectable version priced at $349, signaling a shift from high pricing to broader market coverage [7]. - The company has partnered with the Trump administration to offer oral Wegovy at discounted prices through the upcoming government-operated platform TrumpRx, enhancing drug accessibility [7]. - Novo Nordisk's distribution strategy includes partnerships with over 70,000 pharmacies and telehealth platforms like Ro and Weight Watchers, facilitating direct access to patients through a vertically integrated model [7]. Group 3: Competitive Landscape - Despite its current success, Novo Nordisk's advantage is not guaranteed, as Eli Lilly is advancing its oral small molecule GLP-1 drug, orforglipron, which may present new competition due to its lack of strict post-dosing dietary restrictions [10]. - Analysts project that oral Wegovy's long-term annual sales could reach approximately $3.3 billion, which, while only a fraction of the injectable version's potential, is seen as a critical strategic asset for Novo Nordisk in the obesity market [10].